Wiki Article
Tanawisa
Nguồn dữ liệu từ Wikipedia, hiển thị bởi DefZone.Net
| Company type | Private |
|---|---|
| Industry | Biotechnology |
| Founded | March 3, 2022 |
| Headquarters | Klaeng district, Rayong Province, Thailand |
| Products | Trichuris suis ova |
| Website | tanawisa |
Tanawisa is a Thai biotechnology company that produces Trichuris suis ova (TSO), the eggs of the porcine whipworm. The company supplies TSO for use in helminthic therapy, an experimental immunotherapy based on the hygiene hypothesis.[1][2]
History
[edit]Research into TSO as a potential therapeutic began in the mid-1990s by gastroenterologist Joel Weinstock at the University of Iowa.[3][4] Commercial production was initially developed by the German company Ovamed GmbH, founded in 2003. After failed Phase 2 trials and Ovamed's insolvency, production continued with the original TSO formulation.
TSO production was later managed by Biomonde Thailand before becoming independent. Tanawisa Company Limited was registered on March 3, 2022.[5] The product is approved by the Thai FDA as a natural remedy and has been permitted for export since 2006. It is not approved as a pharmaceutical by major regulatory agencies like the U.S. FDA or the EMA.
Products
[edit]Tanawisa's primary product is TSO, a suspension of Trichuris suis eggs in a pH 2.4 buffer solution, supplied in vials containing 500 to 2500 eggs.
Research and criticism
[edit]TSO has been studied in clinical trials for conditions like Crohn's disease and ulcerative colitis. Early small studies showed potential benefit,[3][4] but larger subsequent trials yielded inconclusive results.[6] A 2021 Phase 1 safety study reported mild gastrointestinal side effects but no serious adverse events.[7]
Helminthic therapy remains controversial and is not endorsed by mainstream medical authorities due to a lack of robust evidence for efficacy and potential safety risks, including infection.[8][9]
References
[edit]- ^ Smyth, K.; Morton, C.; Smyth, M.; Parker, W. (2022). "Socio-medical studies of individuals self-treating with helminths provide insight into clinical trial design for assessing helminth therapy". Parasitology International. 87: 102548. doi:10.1016/j.parint.2021.102548 (inactive 19 December 2025). PMID 34915160. Retrieved 11 December 2025.
{{cite journal}}: CS1 maint: DOI inactive as of December 2025 (link) CS1 maint: article number as page number (link) - ^ Gordon, C. A.; Kurscheid, J.; Jones, M. K.; Gray, D. J.; McManus, D. P. (2017). "Soil-Transmitted Helminths in Tropical Australia and Asia". Tropical Medicine and Infectious Disease. 2 (4): 56. doi:10.3390/tropicalmed2040056. PMC 6082059. PMID 30270911.
- ^ a b Summers, R. W.; Elliott, D. E.; Urban, J. F.; Thompson, R.; Weinstock, J. V. (2005). "Trichuris suis therapy in Crohn's disease". Gut. 54 (1): 87–90. doi:10.1136/gut.2004.041749. PMC 1774382. PMID 15591509.
- ^ a b Summers, R. W.; Elliott, D. E.; Urban, J. F.; Thompson, R. A.; Weinstock, J. V. (2005). "Trichuris suis therapy for active ulcerative colitis: a randomized controlled trial". Gastroenterology. 128 (4): 825–832. doi:10.1053/j.gastro.2005.01.005. PMID 15825065.
- ^ "TANAWISA COMPANY LIMITED - 2025 Company Profile & Financials". Tracxn. 18 October 2025. Archived from the original on 11 December 2025. Retrieved 11 December 2025.
- ^ Sandborn, W. J.; Elliott, D. E.; Weinstock, J.; Summers, R. W.; Landry-Wheeler, A.; Silver, N.; Har-Noy, M.; Wallace, M.; Daveson, J.; Phillips, A.; Geraci, N. (2013). "Randomised clinical trial: the safety and tolerability of Trichuris suis ova in patients with Crohn's disease". Alimentary Pharmacology & Therapeutics. 38 (3): 255–263. doi:10.1111/apt.12366. PMID 23730956.
- ^ Hirata, H.; Kasugai, D.; Kunisawa, K.; Sakaguchi, S.; Kagawa, K.; Kim, H.; Tomigahara, Y.; Kimura, R.; Inoue, N.; Kashiwagi, H. (2021). "Safety and tolerability of medicinal parasite ova (Trichuris suis) in healthy Japanese volunteers: A randomized, double-blind, placebo-controlled trial". Parasitology International. 85: 102445. doi:10.1016/j.parint.2021.102445. PMID 34371190. Retrieved 11 December 2025.
{{cite journal}}: CS1 maint: article number as page number (link) - ^ Garg, S. K.; Croft, A. M.; Bager, P. (2014). "Helminth therapy (worms) for induction of remission in inflammatory bowel disease". Cochrane Database of Systematic Reviews (1): CD009400. doi:10.1002/14651858.CD009400.pub2. PMID 24442917.
{{cite journal}}: CS1 maint: article number as page number (link) - ^ Centers for Disease Control and Prevention. "Parasites - Trichuriasis". CDC. Retrieved 11 December 2025.